Abstract: Provided is a test method for acute kidney injury, including detecting urinary podocalyxin. According to the test method, a subject to be tested who has a higher value for the urinary podocalyxin than a reference value can be assessed to have acute kidney injury. Further, as compared to a conventional method, the test method allows acute kidney injury to be assessed accurately and non-invasively, which allows a physical burden on a patient to be reduced. Thus, the test method is useful.

Abstract: It is intended to provide a safe and efficient method of producing a virus which is free from animal-origin components in the whole process from culturing adhesive cells to producing the virus on an industrial scale by the cell culture. Namely, a method of producing a virus comprising: adhering adhesive cells to a support which has a polypeptide (P) having at least one cell-adhesive minimum amino acid sequence (X) per molecule, and is free from animal-origin components; culturing the adhesive cells in a medium free from animal-origin components; subculturing the cultured adhesive cells using a cell dispersing agent: free from animal-origin components; and then inoculating and proliferating a virus in the cells obtained by culturing the adhesive cells.

Abstract: According to the present invention, an antibody against a Panton-Valentine leukocidin toxin contained in Staphylococcus aureus, a method and a kit for detecting the toxin with the use of the antibody, and a pharmaceutical composition containing an antibody against a Panton-Valentine leukocidin toxin for treating PVL infection caused by Staphylococcus aureus containing PVL are provided. Also, an antibody which is capable of binding to Panton-Valentine leukocidin F and has no cross-reactivity to LukD and/or HlgB and an antibody which is capable of binding to Panton-Valentine leukocidin S and has no cross-reactivity to at least one of LukE, HlgC, and HlgA are provided.

Abstract: Provided is a test method for the assessment of the necessity of renal biopsy in a subject to be tested, who is suspected of having a renal disease. Specifically provided are a test method for a renal disease, including using urinary podocalyxin and one or more additional markers in combination, and a test reagent for use in the test method and a test reagent kit for use in the test method. The present invention allows the discrimination of a poor prognosis group even for poor prognosis cases with no overt findings in a conventional test method, and thus allows the assessment of a renal disease, the assessment of the necessity of renal biopsy, prognostic prediction, and the like to be performed exactly.

Abstract: Provided is a test method for the detection of diabetic nephropathy at an early stage as compared to a conventional method. Specifically provided are: a test method for diabetic nephropathy, including detecting urinary podocalyxin; the test method, further including assessing diabetic nephropathy at least Stage I; a test reagent for use in the test method; and a test reagent kit for use in the test method. The present invention is based on a finding that urinary podocalyxin reflects the development and condition of diabetic nephropathy with high sensitivity at an early stage as compared to urinary albumin.

Abstract: A polynucleotide base sequence represented by SEQ ID NO: 22, a vector containing the polynucleotide and a method of preparing a small round structure virus (SRSV) virus-like particle in insect cells with vector.

Abstract: The present invention is intended to provide a method for simultaneously measuring cholesterol in low density lipoprotein and total cholesterol as test components in blood. Specifically, a method is used for simultaneously measuring cholesterol in low density lipoprotein and total cholesterol in a biological sample, whereby cholesterol in low density lipoprotein and total cholesterol in a biological sample are quantified with a single measurement.

Abstract: Object: To provide a test reagent for the analyte in a test sample, utilizing the level of agglutination of a particle suspension which suspend insoluble carrier particles carrying a substance for capturing the analyte as an indicator, which reagent does not undergo self-agglutination during storage, and which non-specific agglutination rarely occurs during measurement, as well as to provide a method for the analyte to be measured in a test sample. Means for Solution: The test reagent for the analyte comprises at least a Solution A which is a buffer solution having an electric conductivity of not less than 30 ms/cm; and a Solution B having an electric conductivity of not more than 6.5 ms/cm, the Solution B being a particle suspension which suspends particles which are insoluble carrier particles carrying a substance for capturing the analyte.

Abstract: Disclosed is a simple device for a membrane assay using the lateral flow immunoassay method, whereby a subject to be detected can be detected at a high sensitivity, provided with, as a label drying pad, a substrate which has a higher tensile strength than glass fiber and can well release a label. The present invention provides a simple membrane assay device, comprising: a supporting board, a sample supply part, a label containing a labeling component which labels a subject to be detected, a development part formed with a detection part which includes a trapping reagent for detecting or quantifying the subject to be detected, and an absorption part, wherein a non-woven fabric which includes fibers having a fiber diameter of 0.05 to 10 ?m is used in the labeling component part.

Abstract: Described are a urine pretreatment agent, a urine pretreatment method, and a urinary protein quantitation method which reduce or cancel the influences of urine pH variations, cancel the influences of precipitates of urinary inorganic salts, and solubilize membrane proteins. The urine pretreatment agent for urinary protein quantitation, includes a buffer, a chelating agent, and a surfactant; the urine pretreatment method includes a step of mixing 10 to 1000 parts by mass of the urine pretreatment agent of the present invention with 100 parts by mass of urine; and the urinary protein quantitation method includes steps of: mixing 10 to 1000 parts by mass of the urine pretreatment agent with 100 parts by mass of urine; and then measuring the protein concentration.

Abstract: An object of the present invention is to provide an excellent method for detection and diagnosis of familial combined hyperlipidemia. The present invention relates to a method for detection of familial combined hyperlipidemia by measuring the concentration of small, dense LDL cholesterol in a sample collected from a subject.

Abstract: This invention relates to an SRSV detection kit comprising all antibodies against SRSV-related virus constituting peptides selected from the following peptide groups (a) to (k), respectively: (a) a peptide having an amino acid sequence represented by SEQ ID NO: 1, and the like, (b) a peptide having an amino acid sequence represented by SEQ ID NO: 2, and the like, (c) a peptide having an amino acid sequence represented by SEQ ID NO: 3, and the like, (d) a peptide having an amino acid sequence represented by SEQ ID NO: 4, and the like, (e) a peptide having an amino acid sequence represented by SEQ ID NO: 5, and the like, (f) a peptide having an amino acid sequence represented by SEQ ID NO: 6, and the like, (g) a peptide having an amino acid sequence represented by SEQ ID NO: 7, and the like, (h) a peptide having an amino acid sequence represented by SEQ ID NO: 8, and the like, (i) a peptide having an amino acid sequence represented by SEQ ID NO: 9, and the like, (j) a peptide having an amino acid sequence repre

Abstract: A reagent for fractional measurement of small, dense LDLs without pretreatment of a specimen, which is adaptable to a rapid and convenient autoanalyzer, is provided. A method for quantitatively determining cholesterol in small, dense LDLs in a sample is further provided. The method includes first step of eliminating lipoproteins other than small, dense LDLs in a sample in the presence of cholesterol esterase and 0.05 g/L to 1.0 g/L of a surfactant that acts on the lipoproteins other than small, dense LDLs, and a second step of quantitatively determining cholesterol in small dense LDLs that remain after the first step.

Abstract: This invention provides an immunochromatography detection apparatus exhibiting excellent convenience, sensitivity, and specificity, a detection method therefore, a kit using the same, and a method for producing such apparatus and kit, by constructing a solid-phase support, on which the conditions for the reaction wherein an analyte specifically binds to a labeled reagent containing a ligand that specifically binds to the analyte and those for the reaction wherein a capture reagent specifically binds to a complex of the analyte and the labeled reagent in the immunochromatography detection method are continuously optimized, and the pretreated specimens are optimized for such reactions.

Abstract: A test device provided with a reference display section that rapidly and clearly indicates proper test completion with improved accuracy and stability is provided. Such test device is a test device for membrane assay using a specific binding reaction of a substance to be detected with a capture reagent immobilized on a membrane carrier and a reagent labeled with a labeling substance, which comprises a reference display section for indicating proper test completion on which a cationic polymer for capturing a labeled reagent has been immobilized.

Abstract: The present invention relates to a diluent for a Norovirus or Sapovirus specimen, the diluent containing an alkaline buffer of pH 9.0 to 10.0, and to a method for detecting a Norovirus or a Sapovirus through use of the diluent. According to the present invention, a Norovirus or a Sapovirus can be detected in a Norovirus- or Sapovirus-containing specimen such as stool, vomit, body fluid, blood, body tissue, or food, in a convenient manner without use of a special machine such as a centrifuge, with an improved detection sensitivity, and with complete elimination of non-specific factors.

Abstract: This invention provides a method for measuring human megalin that can be performed in a simpler manner within a shorter period of time than is possible with conventional techniques, and that can also quantify human megalin. This invention also provides a method that enables diagnosis of functional diseases, which are specific to cells, tissues, or organs, in a site-directed manner at an early stage. Measurement of human megalin enables detection of a disease in an organ in which megalin expression is observed.

Abstract: A latex agglutination method by which the measurement range is extended and the sensitivity of the measurement in the low concentration range is increased, is disclosed. The method for measuring a test antigen by latex agglutination uses two types of large and small particles, having different average particle sizes. Each latex particle is sensitized with an antibody which undergoes antigen-antibody reaction with the test antigen. The purity of the antibody immobilized on the latex particles is within a specific range. The ratio of the amount of the antibody immobilized per one small latex particle to the amount of the antibody immobilized per one large latex particle; the average particle size of the large latex particles; the average particle size of the small latex particles; the concentration of the large sensitized latex particles in the antigen-antibody reaction system; and the concentration of the small sensitized latex particles in the reaction system are within a specific range.

Abstract: The present invention provides a fast and simple method for fractional measurement of small particle low density lipoprotein (LDL). The method for quantifying small particle LDL in a test sample entails a first step of separating the small particle LDL from other low density lipoproteins, and a second step of measuring cholesterol, triglycerides or proteins in the separated small particle LDL.

Abstract: Provided is a method of stabilizing a reagent that allows simultaneous quantification of LDL cholesterol and total cholesterol by a single measurement by suppressing spontaneous color development thereof. A method of quantification for cholesterol in low density lipoprotein and total cholesterol in a biological sample by the single measurement comprises a first step of treating lipoproteins other than low density lipoprotein in the biological sample to generate hydrogen peroxide and a second step of converting the hydrogen peroxide obtained in the first step to a quinone dye and treating remaining low density lipoprotein and converting generated hydrogen peroxide to the quinone dye, where the quinone dye is not formed in the first step, and cholesterol in low density lipoprotein and total cholesterol are quantified from the amount of the quinone dye formed in the second step by the single measurement.